Home » Stocks » NKTR

Nektar Therapeutics (NKTR)

Stock Price: $16.24 USD -0.27 (-1.64%)
Updated Jul 26, 2021 4:00 PM EDT - Market closed
After-hours: $16.58 +0.34 (2.09%) Jul 26, 5:42 PM
Market Cap 2.97B
Revenue (ttm) 125.99M
Net Income (ttm) -428.76M
Shares Out 181.37M
EPS (ttm) -2.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 26
Last Price $16.24
Previous Close $16.51
Change ($) -0.27
Change (%) -1.64%
Day's Open 16.42
Day's Range 16.14 - 16.59
Day's Volume 542,648
52-Week Range 15.40 - 26.75

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SAN FRANCISCO, July 19, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that it has appointed Dimitry S.A. Nuyten, M.D.

1 week ago - PRNewsWire

SAN FRANCISCO, June 7, 2021 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) senior management is scheduled to participate in a virtual fireside chat at the upcoming Goldman Sachs 42nd Annual Global ...

1 month ago - PRNewsWire

SAN FRANCISCO, May 20, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of preclinical data in the Journal of Translational Autoimmunity describing NKTR-358, a fir...

2 months ago - PRNewsWire

SAN FRANCISCO, May 18, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of preclinical data from its second major immuno-oncology cytokine program, NKTR-255, in th...

2 months ago - PRNewsWire

Nektar (NKTR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

2 months ago - Zacks Investment Research

Nektar (NKTR) delivered earnings and revenue surprises of 5.56% and -18.18%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

SAN FRANCISCO, May 6, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2021. Cash and investments in marketable securities a...

2 months ago - PRNewsWire

Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

SAN FRANCISCO, April 27, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2021 on Thursday, May 6, 2021, after the close of U.S.-based fi...

2 months ago - PRNewsWire

Nektar (NKTR) reported earnings 30 days ago. What's next for the stock?

3 months ago - Zacks Investment Research

Last month we talked about how Nektar Therapeutics stock seems to be a good buying opportunity, and now there have been more positive developments for the company. Last week, Nektar announced that it ha...

4 months ago - Forbes

Nektar (NKTR) reports encouraging fourth-quarter 2020 results. The company plans to initiate a new registrational study on its lead pipeline candidate, bempegaldesleukin, in 2021.

5 months ago - Zacks Investment Research

SAN FRANCISCO, Feb. 25, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2020. Cash and investments in mar...

5 months ago - PRNewsWire

Nektar (NKTR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

5 months ago - Zacks Investment Research

SAN FRANCISCO, Feb. 18, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2020, on Thursday, February 25, 202...

5 months ago - PRNewsWire

Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Nektar's (NKTR) shares up following a deal with Merck for a combination study of bempegaldesleukin with Keytruda for advanced head and neck cancer study.

5 months ago - Zacks Investment Research

Nektar Therapeutics (NASDAQ: NKTR) announces a financing and co-development collaboration with privately-held SFJ Pharmaceuticals to develop Bempegaldesleukin (BEMPEG) CD122-preferential IL-2–pathway ag...

5 months ago - Benzinga

As the Dow, S&P 500, and Nasdaq keep up the good news, Q.ai's Artificial Intelligence systems have crunched the data to give you today's best short plays.

Other stocks mentioned: ELF, EOG, FUN, SGMS
5 months ago - Forbes

Nearly all of last week's losses have been recovered, and investors seem to be back to focusing on earnings from tech giants, stimulus progress, and the vaccine. With all of this news, Q.ai's deep learn...

Other stocks mentioned: BATRK, FUN, REZI, WDC
5 months ago - Forbes

The GameStop effect will soon come to biopharma, an usually heavily-shorted sector. Here's a list of three of biopharma's more heavily-shorted stocks.

Other stocks mentioned: LGND, MDGL
5 months ago - Seeking Alpha

A recap for my 20/20 Vision is offered for my readers. I will share my concerns about the current market conditions.

Other stocks mentioned: AMPH, AQUA, BBDC, BHVN, CFX, CRHM, GBT ...
6 months ago - Seeking Alpha

These stocks have one obvious thing in common.

Other stocks mentioned: AMRN, BLUE
6 months ago - The Motley Fool

SAN FRANCISCO, Jan. 6, 2021 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard Robin, is scheduled to present at the upcoming 39th Annual J.P. Morgan Virtu...

6 months ago - PRNewsWire

We believe that Nektar Therapeutics stock, a biopharmaceutical company focused on discovering and developing medicines in areas that include cancer, autoimmune disease, and chronic pain, is a good buyin...

6 months ago - Forbes

These are the stocks posting the largest moves after hours on Tuesday.

Other stocks mentioned: CALM, MYGN, SGH
6 months ago - CNBC

SAN FRANCISCO, Jan. 5, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) announced today that it has appointed Brian Kotzin, MD as Interim Chief Medical Officer, Head of Development effective imme...

6 months ago - PRNewsWire

Investors need to pay close attention to Nektar Therapeutics (NKTR) stock based on the movements in the options market lately.

7 months ago - Zacks Investment Research

Nektar (NKTR) doses the first patient in a phase I/II study on NKTR-255 in combination with Erbitux for treating head and neck squamous cell carcinoma or colorectal cancer. Shares up.

7 months ago - Zacks Investment Research

SAN FRANCISCO, Dec. 7, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced two nonclinical data presentations for NKTR-255, its IL-15 pathway agonist, at the 62nd American Society of...

7 months ago - PRNewsWire

Nektar (NKTR) reported earnings 30 days ago. What's next for the stock?

7 months ago - Zacks Investment Research

Nectar, a global leader in polymer chemistry-based drug discovery, has no major near-term catalysts, a vast pipeline and numerous big pharma collaborations. It recently published a set of 3 trial data a...

8 months ago - Seeking Alpha

SAN FRANCISCO, Nov. 11, 2020 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced four data presentations for its I-O pipeline from three separate clinical-stage investigational agents at ...

8 months ago - PRNewsWire

Nektar (NKTR) reports encouraging third-quarter 2020 results. Enrollment in clinical studies back on track.

8 months ago - Zacks Investment Research

Nektar Therapeutics (NKTR) CEO Howard Robin on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Nektar (NKTR) delivered earnings and revenue surprises of 23.75% and 39.34%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

SAN FRANCISCO, Nov. 5, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today reported financial results for the third quarter ended September 30, 2020. Cash and investments in marketable securit...

8 months ago - PRNewsWire

SAN FRANCISCO, Nov. 4, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced the presentation of additional clinical data from the Phase 1b study evaluating multiple ascending doses of NKTR-3...

8 months ago - PRNewsWire

SAN FRANCISCO, Oct. 29, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) announced today that it will webcast an analyst and investor conference call at ACR 2020 with company management and Dr. K...

8 months ago - PRNewsWire

Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

8 months ago - Zacks Investment Research

SAN FRANCISCO, Oct. 28, 2020 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2020 on Thursday, November 5, 2020, after the close of U.S.-base...

8 months ago - PRNewsWire

SAN FRANCISCO, Oct. 27, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that it has received FDA clearance for an Investigational New Drug (IND) application for its investigation...

8 months ago - PRNewsWire

Nektar (NKTR) reported earnings 30 days ago. What's next for the stock?

10 months ago - Zacks Investment Research

Nektar is largely marking time ahead of some "medium impact" trial updates in November and game-changing updates in 2021 for the melanoma and bladder cancer programs.

10 months ago - Seeking Alpha

Nektar (NKTR) reports encouraging second-quarter 2020 results. The company continues to progress with its pipeline candidates.

11 months ago - Zacks Investment Research

Nektar Therapeutics (NKTR) CEO Howard Robin on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Nektar (NKTR) delivered earnings and revenue surprises of 34.78% and 113.84%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

SAN FRANCISCO, Aug. 6, 2020 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2020.

11 months ago - PRNewsWire

Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

11 months ago - Zacks Investment Research

SAN FRANCISCO, July 28, 2020 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2020 on Thursday, August 6, 2020, after the close of U.S.-based...

11 months ago - PRNewsWire

About NKTR

Nektar Therapeutics operates as a biopharmaceutical company. The company researches and develops pipeline of investigational medicines in oncology, immunology, and virology, as well as a portfolio of approved partnered medicines. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma and ... [Read more...]

Industry
Biotechnology
IPO Date
May 3, 1994
CEO
Howard Robin
Employees
718
Stock Exchange
NASDAQ
Ticker Symbol
NKTR
Full Company Profile

Financial Performance

In 2020, NKTR's revenue was $152.92 million, an increase of 33.41% compared to the previous year's $114.62 million. Losses were -$444.44 million, 0.86% more than in 2019.

Financial Statements

Analyst Forecasts

According to 15 analysts, the average rating for NKTR stock is "Buy." The 12-month stock price forecast is 31.30, which is an increase of 92.73% from the latest price.

Price Target
$31.30
(92.73% upside)
Analyst Consensus: Buy